← Back to patent-cliff list
ECI-830
Tier C — Watch / tradeECI-830
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDK2
Indications (approved)：Solid tumour, HR阳性乳腺癌, Small cell lung cancer
Regional status
US
Phase II
2025-04-03
EU
Phase II
2025-04-03
China
Phase II
2025-04-03
Japan
Phase II
2025-04-03
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ECI-830?
Approved indications include: Solid tumour, HR阳性乳腺癌, Small cell lung cancer.
When does the ECI-830 patent expire?
No public expiry year is available for ECI-830 yet; this page updates once verified.
How do I get a quote for ECI-830 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30